Implantable Drug Infusion Pumps Market

Implantable Drug Infusion Pumps Market By Product Type (PCA Pumps, Enteral Pumps, Insulin Pumps, Elastomeric Pumps, Syringe Pumps); By Application (Oncology, Pediatrics/Neonatology, Gastroenterology, Hematology, Diabetes); By End User (Hospitals, Ambulatory Surgical Centers, Clinics, Home Healthcare) - Global Demand Analysis & Opportunity Outlook 2027

Buy Now
Report ID: 631 | Published On: Oct 06, 2022
  1. Introduction
    • Market Definition
    • Market Segmentation
    • Product Overview
  2. Assumptions and Acronyms
  3. Research Methodology
  4. Research Process
    • Primary Research
    • Manufacturers
    • Distributors
    • End Users
    • Secondary Research
    • Market Size Estimation
  5. Executive Summary - Global Advanced Therapy Medicinal Products Market
  6. Analysis of Market Dynamics
  7. Drivers
  8. Trends
  9. Key Market Opportunities for Business Growth
  10. Major Roadblocks for the Market Growth
  11. Regulatory & Standard Landscape
  12. Value Chain Analysis
  13. Potential ATMP Treatment Analysis
  14. Pricing Analysis of Global Advanced Therapy Medicinal Products Market
  15. Use Case Analysis
  16. Pipeline Analysis
  17. Analysis on the Manufacturing Process
  18. Analysis of COVID-19 Impact on the Global Advanced Therapy Medicinal Products Market
  19. Analysis of End-User Market Share of Global Advanced Therapy Medicinal Products
  20. Competitive Positioning
  21. Competitive Landscape
  22. Market Share Analysis of Major Players (%), 2021
  23. Competitive Benchmarking
  24. Novartis AG.
  25. Takeda Pharmaceutical Company Limited
  26. Gilead Sciences, Inc.
  27. Bluebird Bio, Inc
  28. BioMarin Pharmaceutical Inc
  29. Vericel Corporation
  30. Mallinckrodt Pharmaceuticals
  31. UniQure N.V.
  32. JCR Pharmaceuticals Co., Ltd.
  33. Spark Therapeutics, Inc. (Parent Company: Roche)
  34. Kolon TissueGene, Inc.
  35. Global Advanced Therapy Medicinal Products Market Outlook
  36. By Value (USD million)
  37. By Product
  38. CAR-T Therapy, 2021-2031F (USD million)
  39. Gene Therapy, 2021-2031F (USD million)
  40. Cell Therapy, 2021-2031F (USD million)
  41. Tissue Engineered Product, 2021-2031F (USD million)
  42. By Disease
  43. Oncology, 2021-2031F (USD million)
  44. Genetic Disorders, 2021-2031F (USD million)
  45. CNS, 2021-2031F (USD million)
  46. Dermatology, 2021-2031F (USD million)
  47. Others, 2021-2031F (USD million)
  48. By End-User
  49. Hospitals & Clinics, 2021-2031F (USD million)
  50. Research & Academic Institutes, 2021-2031F (USD million)
  51. Global Advanced Therapy Medicinal Products Market by Region
  52. North America, 2021-2031F (USD million)
  53. Europe, 2021-2031F (USD million)
  54. Asia-Pacific, 2021-2031F (USD million)
  55. Latin America, 2021-2031F (USD million)
  56. Middle East & Africa, 2021-2031F (USD million)
  57. North America Advanced Therapy Medicinal Products Market Outlook
  58. By Value (USD million)
  59. By Product
  60. CAR-T Therapy, 2021-2031F (USD million
  61. Gene Therapy, 2021-2031F (USD million)
  62. Cell Therapy, 2021-2031F (USD million)
  63. Tissue Engineered Product, 2021-2031F (USD million)
  64. By Disease
  65. Oncology, 2021-2031F (USD million)
  66. Genetic Disorders, 2021-2031F (USD million)
  67. CNS, 2021-2031F (USD million)
  68. Dermatology, 2021-2031F (USD million)
  69. Others, 2021-2031F (USD million)
  70. By End-User
  71. Hospitals & Clinics, 2021-2031F (USD million)
  72. Research & Academic Institutes, 2021-2031F (USD million)
  73. By Country
  74. US, 2021-2031F (USD million)
  75. Canada, 2021-2031F (USD million)
  76. Europe Advanced Therapy Medicinal Products Market Outlook
  77. By Product
  78. By Disease
  79. By End User
  80. By Country
  81. UK, 2021-2031F (USD Million)
  82. Germany, 2021-2031F (USD Million)
  83. France, 2021-2031F (USD Million)
  84. Italy, 2021-2031F (USD Million)
  85. Spain, 2021-2031F (USD Million)
  86. Russia, 2021-2031F (USD Million)
  87. Netherlands, 2021-2031F (USD Million)
  88. Rest of Europe, 2021-2031F (USD Million)
  89. Asia Pacific Advanced Therapy Medicinal Products Market Outlook
  90. By Product
  91. By Disease
  92. By End User
  93. By Country
  94. China, 2021-2031F (USD Million)
  95. India, 2021-2031F (USD Million)
  96. Japan, 2021-2031F (USD Million)
  97. South Korea, 2021-2031F (USD Million)
  98. Singapore, 2021-2031F (USD Million)
  99. Australia, 2021-2031F (USD Million)
  100. Rest of Asia-Pacific, 2021-2031F (USD Million)
  101. Latin America Advanced Therapy Medicinal Products Market Outlook
  102. By Product
  103. By Disease
  104. By End User
  105. By Country
  106. Brazil, 2021-2031F (USD Million)
  107. Argentina, 2021-2031F (USD Million)
  108. Mexico, 2021-2031F (USD Million)
  109. Rest of Latin America, 2021-2031F (USD Million)
  110. Middle East & Africa Advanced Therapy Medicinal Products Market Outlook
  111. By Product
  112. By Disease
  113. By End User
  114. By Country
  115. GCC, 2021-2031F (USD Million)
  116. Israel, 2021-2031F (USD Million)
  117. South Africa, 2021-2031F (USD Million)
  118. Rest of Middle East & Africa, 2021-2031F (USD Million)

Preview Analysis

Request Insights
Inflation and Looming Recession to Haunt Businesses:

In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.


In The News


Implantable Drug Infusion Pumps Market Overview

Implantable Drug Infusion Pumps are entrenched under the skin by means of surgery. These infusion devices discharge medications through a pipe or tube to a particular body part. Implantable drug infusion system ensures steady supply and is highly advisable during long-term medications. The delivery of constant medication from infusion systems helps in the reduction of pain when oral or topical medicines are incapable of providing effective results. An implantable drug infusion system have various potential benefits such as reducing the side effects and chronic pain in comparison to other forms of drug delivery, providing relief to the patient from direct injections or discomfort of catheters and provides better symptoms management.


Market Size & Forecast

Implantable drug infusion pump market is anticipated to record a significant CAGR over the forecast period. Many multi-national companies are concentrating towards new product advances in Implantable Drug Infusion Pumps. Also, the market for implantable drug infusion pumps would experience a lift due to rising prevalence of pain, diabetes and cancer, rapid growth in elderly population, technological developments such as growth in wireless technology, introduction of smart pumps and rise in healthcare expenditure globally.

The competition in the drug infusion market is based on the costs, brand value, advances and customer services. To uphold in the market, various strategies such as acquisitions and mergers, licensing and agreements are being undertaken by market players. In 2016, the large volume infusion pump system accounted for the highest market share on a global scale, among the product types.

On the basis of regional platform, global implantable drug infusion pumps market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.

North America is the most appealing region for the implantable drug infusion system market attributing to the robust pharmaceutical industry. A significant number of foremost players are located in this region, rising number of partnerships between technology providers and drug companies, followed by Europe as the leading regions in implantable drug infusion system market. These markets are also swelling significantly owing to emphasis on the new product developments for portable and lightweight Implantable Drug Infusion Pumps that would relieve in the drug delivery method and favorable regulatory environment.

Implantable Drug Infusion Pumps  Market

Asia Pacific is estimated to show substantial growth due to saturation in the major economies, rise in R&D activities and development of healthcare infrastructure in Implantable Drug Infusion Pumps market. Asia-Pacific region has the presence of many small players which are functioning at a regional level and add up to a significant market share of the Implantable Drug Infusion Pumps market.CLICK TO DOWNLOAD FREE SAMPLE


Market Segmentation

Our-in depth analysis of the global Implantable Drug Infusion Pumps market includes the following segments:

By Product Type

  • Patient-Controlled Analgesia (PCA) Pumps
  • Enteral Pumps
  • Insulin Pumps
  • Elastomeric Pumps
  • Syringe Pumps

By Application

  • Oncology
  • Pediatrics/Neonatology
  • Gastroenterology
  • Hematology
  • Diabetes

 By End-User

  • Hospitals
  • Ambulatory Surgical Centers
  • Clinics
  • Home Healthcare

By Region

Global Implantable Drug Infusion Pumps Market is further classified on the basis of region as follows:

  • North America (United States, Canada), Market size, Y-O-Y growth Market size, Y-O-Y growth & Opportunity Analysis, Future forecast & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of LATAM), Market size, Y-O-Y growth, Future forecast & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, BENELUX (Belgium, Netherlands, Luxembourg), NORDIC (Norway, Denmark, Sweden, Finland), Poland, Russia, Rest of Europe), Market size, Y-O-Y growth, Future forecast & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Malaysia, Indonesia, Taiwan, Hong Kong, Australia, New Zealand, Rest of Asia-Pacific), Market size, Y-O-Y growth, Future forecast & Opportunity Analysis
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa), Market size, Y-O-Y growth, Future forecast & Opportunity Analysis

Implantable Drug Infusion Pumps  Market share


Implantable Drug Infusion Pumps  Market
Get more information on this report: Request Sample PDF

Growth Drivers & Challenges

The Implantable Drug Infusion Pumps market includes numerous infusion system products including components such as pumps, accessories and disposables. The increased occurrence of chronic diseases and the growing elderly population has led to the increased demand for improved medicines and services. For the continued and improved care of the patients, the drug infusion systems are being extensively exercised in the hospitals as well as the home care settings. The rising prevalence of chronic diseases is another factor contributing to the growth of the market. In the recent years, the prevalence of chronic diseases has been increasing irrespective of the age. The prevalence of genetic diseases and cancer has also witnessed a rise in the recent years that will perform as growth drivers for this market.

However, implantable drug infusion systems market would be affected owing to cost constraints, strict regulations for new products due to patient safety risks and low reimbursement for Implantable Drug Infusion Pumps in the developing countries. In 2013, U.S. Food and Drug Administration Safety Information and Adverse Event Reporting Program announced, regarding various product withdrawals due to malfunctioning of Implantable Drug Infusion Pumps which delivered drug overdose leading to risks in patient safety. These factors have refrained the patients from the adoption of Implantable Drug Infusion Pumps.


Key Players
  • B. Braun Melsungen AG.
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
  • CareFusion Corporation
  • Fresenius Kabi AG
  • Terumo Corporation
  • Medtronic Plc.
  • Baxter International Inc.
  • Smiths Medical
  • MOOG Inc.
  • Johnson & Johnson Private Ltd.
  • Hospira, Inc.


Implantable Drug Infusion Pumps  Market share
Let Us Hear About Your Requirements:

Submit Your Request For Proposal (RFP)

Submit RFP    Buy Now Download Research Report Sample